The new data – from the ARISE trial – found that Cobenfy wasn't statistically better than placebo at improving the widely ...

Cobenfy’s late-stage flop is BMS’ second high-profile failure in as many weeks. The pharma announced last week that Camzyos ...

US pharma major Bristol Myers Squibb (NYSE: BMY) saw its shares fall 4% in after-hours trading on Tuesday, after it announced ...

In the Phase III ARISE trial, Cobenfy administered as an adjunctive treatment to atypical antipsychotics for patients with ...

Schizophrenia drug Cobenfy, a key component in Bristol Myers Squibb’s plan to navigate a transition period of major loss of ...

BMS has reported topline outcomes from the ARISE trial of Cobenfy as an adjunctive treatment to atypical antipsychotics for ...

Cobenfy (xanomeline and trospium chloride) as an adjunctive treatment to atypical antipsychotics demonstrated a 2.0-point ...

Cobenfy, Bristol Myers Squibb’s once-promising schizophrenia drug, just failed its Phase III ARISE trial as an add-on therapy ...

Bristol Myers Squibb & Co (NYSE:BMY) on Tuesday released topline results from the Phase 3 ARISE trial evaluating the efficacy ...

The new schizophrenia drug didn’t provide additional benefits when given on top of standard-of-care therapy, Bristol Myers ...

In the phase III ARISE trial, adjunctive xanomeline and trospium chloride (Cobenfy) were no better than placebo at improving ...

A late-stage study found Cobenfy wasn’t better than a placebo as an add-on to atypical antipsychotics. Some analysts view the failure as a “significant hit” to the drug’s commercial outlook.